Washington, D.C. 20549


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Scadden David

(Last) (First) (Middle)


(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $33.36 06/03/2021 A 11,538 (1) 06/02/2031 Common Stock 11,538 $0 11,538 D
Explanation of Responses:
1. This option was granted on June 3, 2021 and is scheduled to vest in full on June 3, 2022.
/s/ David Scadden 06/04/2021
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

    Know all by these present, that the undersigned
hereby makes, constitutes and appoints each of
Michelle Robertson, Charlene Stern-Dombal, Damien
Grierson and Erica Iorio, signing singly and each
acting individually, as the undersigned's true and
lawful attorney-in-fact with full power and authority
as hereinafter described to:

    (1)  execute for and on behalf of the undersigned,
in the undersigned's capacity as a director, officer
and/or stockholder of Editas Medicine, Inc. (the
"Company"), Forms 3, 4, and 5 (including any
amendments thereto) in accordance with Section 16(a)
of the Securities Exchange Act of 1934 and the rules
thereunder (the "Exchange Act");

    (2)  do and perform any and all acts for and on
behalf of the undersigned which may be necessary or
desirable to prepare, complete and execute any such
Form 3, 4, or 5, prepare, complete and execute any
amendment or amendments thereto, and timely deliver
and file such form with the United States Securities
and Exchange Commission (the "SEC") and any stock
exchange or similar authority, including without
limitation the filing of a Form ID or any other
application materials to enable the undersigned to
gain or maintain access to the Electronic Data
Gathering, Analysis and Retrieval system of the SEC;

    (3)  seek or obtain, as the undersigned's
representative and on the undersigned's behalf,
information regarding transactions in the Company's
securities from any third party, including brokers,
employee benefit plan administrators and trustees, and
the undersigned hereby authorizes any such third party
to release any such information to the herein
appointed attorney-in-fact and approves and ratifies
any such release of information; and

    (4)  take any other action of any type whatsoever
in connection with the foregoing which, in the opinion
of such attorney-in-fact, may be of benefit to, in the
best interest of, or legally required by, the
undersigned, it being understood that the documents
executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall
be in such form and shall contain such terms and
conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

    The undersigned hereby grants to each such
attorney-in-fact full power and authority to do and
perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the
exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the
undersigned might or could do if personally present,
with full power of substitution or revocation, hereby
ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's
substitute or substitutes, shall lawfully do or cause
to be done by virtue of this power of attorney and the
rights and powers herein granted.  The undersigned
acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the
undersigned, are not assuming nor relieving, nor is
the Company assuming nor relieving, any of the
undersigned's responsibilities to comply with
Section 16 of the Exchange Act.  The undersigned
acknowledges that neither the Company nor the
foregoing attorneys-in-fact assume (i) any liability
for the undersigned's responsibility to comply with
the requirement of the Exchange Act, (ii) any
liability of the undersigned for any failure to comply
with such requirements, or (iii) any obligation or
liability of the undersigned for profit disgorgement
under Section 16(b) of the Exchange Act.

    This Power of Attorney shall remain in full force
and effect until the undersigned is no longer required
to file Forms 3, 4, and 5 with the SEC with respect to
the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier
revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.

    IN WITNESS WHEREOF, the undersigned has caused
this Power of Attorney to be executed as of this 3rd
day of June, 2021.

/s/ David Scadden
Print Name: David Scadden

[Signature Page to Power of Attorney for Section 16 Reporting